(DGX) Quest Diagnostics - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74834L1008
DGX: Diagnostic Tests, Laboratory Services, Medical Information
Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing services in the United States and select international markets. The company operates at the intersection of healthcare and information technology, delivering critical diagnostic data that informs patient care and treatment decisions. With a market capitalization of approximately $18 billion, Quest is a significant player in the health care services sector, offering a wide array of clinical testing services, including routine and specialized lab tests, anatomic pathology, and other advanced diagnostic solutions.
The company serves a diverse customer base, including physicians, hospitals, patients, consumers, health plans, government agencies, employers, retailers, pharmaceutical companies, insurers, and accountable care organizations. This broad reach is supported by a extensive network of laboratories, patient service centers, and mobile healthcare professionals. Quest’s services are delivered under several brands, such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, in addition to its core Quest Diagnostics brand.
Beyond diagnostic testing, Quest provides risk assessment services for the life insurance industry and offers healthcare information technology solutions to organizations and clinicians. These services position the company as a comprehensive provider of diagnostic and health information solutions, making it a critical partner for various stakeholders in the healthcare ecosystem. With a forward P/E ratio of 16.72 and a price-to-book ratio of 2.65, Quest offers investors a balance of growth potential and stability in the healthcare services sector.
Founded in 1967 and headquartered in Secaucus, New Jersey, Quest Diagnostics has established itself as a leader in the diagnostic testing industry. Its scale, diversified revenue streams, and strategic focus on innovation and customer service make it a key player in the evolving healthcare landscape. For more information, visit their website at https://www.questdiagnostics.com.
Additional Sources for DGX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DGX Stock Overview
Market Cap in USD | 19,052m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1996-12-17 |
DGX Stock Ratings
Growth 5y | 69.4% |
Fundamental | 22.6% |
Dividend | 65.3% |
Rel. Strength Industry | 30.8 |
Analysts | 3.94/5 |
Fair Price Momentum | 182.26 USD |
Fair Price DCF | 189.27 USD |
DGX Dividends
Dividend Yield 12m | 2.39% |
Yield on Cost 5y | 4.37% |
Annual Growth 5y | 6.02% |
Payout Consistency | 98.4% |
DGX Growth Ratios
Growth Correlation 3m | 79.2% |
Growth Correlation 12m | 91.4% |
Growth Correlation 5y | 72.3% |
CAGR 5y | 14.09% |
CAGR/Max DD 5y | 0.50 |
Sharpe Ratio 12m | 0.07 |
Alpha | 27.13 |
Beta | 0.22 |
Volatility | 21.85% |
Current Volume | 1436.6k |
Average Volume 20d | 1172.6k |
As of March 12, 2025, the stock is trading at USD 168.15 with a total of 1,436,631 shares traded.
Over the past week, the price has changed by -3.92%, over one month by +0.73%, over three months by +8.53% and over the past year by +32.66%.
Neither. Based on ValueRay Fundamental Analyses, Quest Diagnostics is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 22.60 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DGX as of March 2025 is 182.26. This means that DGX is currently overvalued and has a potential downside of 8.39%.
Quest Diagnostics has received a consensus analysts rating of 3.94. Therefor, it is recommend to buy DGX.
- Strong Buy: 8
- Buy: 1
- Hold: 9
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, DGX Quest Diagnostics will be worth about 196.8 in March 2026. The stock is currently trading at 168.15. This means that the stock has a potential upside of +17.06%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 177 | 5.2% |
Analysts Target Price | 170.4 | 1.3% |
ValueRay Target Price | 196.8 | 17.1% |